The mammalian endothelium expresses two related but distinct receptor tyrosine kinases, VEGFR1 and VEGFR2 [VEGF (vascular endothelial growth factor) receptor 1 and 2], that regulate the vascular response to a key cytokine, VEGF-A. In the present review, we suggest a model for integrating the signals from these receptor tyrosine kinases by co-ordinating the spatial and temporal segregation of these membrane proteins linked to distinct signalling outputs associated with each intracellular location. Activation of pro-angiogenic VEGFR2 stimulates a programme of tyrosine phosphorylation, ubiquitination and proteolysis. This is linked to ESCRT (endosomal sorting complex required for transport)-mediated recognition of activated VEGFR2 and sorting in endosomes before arrival in lysosomes for terminal degradation. In addition, Rab GTPases regulate key events in VEGFR2 trafficking between the plasma membrane, early and late endosomes, with distinct roles for Rab4a, Rab5a and Rab7a. Manipulation of GTPase levels affects not only VEGFR2 activation and intracellular signalling, but also functional outputs such as VEGF-A-stimulated endothelial cell migration. In contrast, VEGFR1 displays stable Golgi localization that can be perturbed by cell stimuli that elevate cytosolic Ca 2+ ion levels. One model is that VEGFR1 translocates from the trans-Golgi network to the plasma membrane via a calcium-sensitive trafficking step. This allows rapid and preferential sequestration of VEGF-A by the higher-affinity VEGFR1, thus blocking further VEGFR2 activation. Recycling or degradation of VEGFR1 allows resensitization of the VEGFR2-dependent signalling pathway. Thus a dual VEGFR system with a built-in negative-feedback loop is utilized by endothelial cells to sense a key cytokine in vascular tissues.
Introduction
The vascular endothelium employs two cell-surface RTKs (receptor tyrosine kinases), VEGFR [VEGF (vascular endothelial growth factor) receptor] 1/Flt-1 (Fms-like tyrosine kinase 1) and VEGFR2/KDR (kinase insert domain receptor), that bind with high affinity to the cytokine VEGF-A, regulating different vascular responses in vertebrates [1, 2] . How is such a dual-RTK system used to regulate the intensity and duration of signal transduction? One obvious cellular mechanism to terminate signalling of an activated receptorligand complex involves increased endocytosis, endosomal transport and sorting to lysosomes for terminal proteolysis. However, there is increasing evidence for RTK-mediated signalling from intracellular compartments other than the Key words: angiogenesis, endocytosis, proteolysis, receptor tyrosine kinase, signalling, vascular endothelial growth factor (VEGF). Abbreviations used: ER, endoplasmic reticulum; ERK1/2, extracellular-signal-regulated kinase 1/2; ESCRT, endosomal sorting complex required for transport; Grb, growth-factor-receptorbound protein; Hrs, hepatocyte growth factor-regulated tyrosine kinase substrate; MAPK, mitogen-activated protein kinase; Nedd4, neural-precursor-cell-expressed developmentally down-regulated 4; PLCγ 1, phospholipase Cγ 1; RNAi, RNA interference; RTK, receptor tyrosine kinase; SH2, Src homology 2; TGN, trans-Golgi network; VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor. 1 To whom correspondence should be addressed (email s.ponnambalam@leeds.ac.uk). plasma membrane [3, 4] . Whereas plasma membrane-linked VEGFR-regulated signal transduction mechanisms are well characterized and have been reviewed extensively [1, 5, 6] , co-ordination of signalling, trafficking and proteolysis from intracellular compartments is not well understood. [7, 8] . However, more recent studies suggest that a proto-oncogene and E3 ubiquitin ligase, c-Cbl, is activated by VEGFR2 and mediates PLCγ 1 recruitment to an activated VEGFR2 complex [9] .
Regulation of VEGFR2 intracellular signalling
Dejana and colleagues have shown that when VEGFR2 is trapped inside endosomes containing phosphorylated PLCγ 1, it is still capable of stimulating MAPK (mitogenactivated protein kinase) signalling [10] . A proposed model suggests that VEGFR2 undergoes constitutive clathrin-dependent endocytosis with recycling from early endosomes ( Figure 1 ). Here, VEGFR2 activation stimulates recognition and sorting by the ESCRT (endosomal sorting complex required for transport) machinery and redirection along a pathway towards terminal degradation in lysosomes. Interestingly, blocking VEGFR2 tyrosine kinase activity using compounds such as SU5416 (an indolinone that resembles the anticancer therapeutic Sutent) can cause VEGFR2 accumulation in endosomes [11] . Hrs (hepatocyte growth factor-regulated tyrosine kinase substrate) displays increased tyrosine phosphorylation after VEGF-A stimulation [11] and is implicated in interaction with VEGFR2 [12] to stimulate endosomal sorting.
Rab GTPases regulate VEGFR2 trafficking and signalling
Rab proteins are Ras-related small GTPases that regulate exocytic and endocytic trafficking in eukaryotes [13, 14] . A key member of this family is the Rab5a GTPase that is associated with early endosomes [15] . Overexpression of the Rab5a GTPase-deficient and constitutively active Q79L mutant caused accumulation of VEGFR2 in enlarged endosomes [16] . Conversely, depletion of Rab5a using RNAi (RNA interference) enhanced VEGFR2 tyrosine phosphorylation and MAPK signalling as evident from enhanced p42/p44 ERK1/2 (extracellular-signal-regulated kinase 1/2) phosphorylation [16] . Thus a clear regulatory role exists for Rab5a both in VE-GFR2 early endosome trafficking and VEGF-A-stimulated signalling. Another GTPase called Rab7a that regulates the transport from the early to late endosomes is also involved in VEGFR2 trafficking and function. Overexpression of Rab7a proteins of either a GDP-bound dominant-negative mutant (T22N) or a GTP-bound constitutively active mutant (Q67L) caused accumulation of VEGFR2 in late endosomes [16] . Interestingly, depletion of Rab7a levels using RNAi decreased VEGFR2 tyrosine phosphorylation, but stimulated p42/p44 ERK1/2 phosphorylation [16] . Importantly, knockdown of Rab GTPase levels using RNAi showed that Rab7a depletion was inhibitory, whereas Rab5a depletion was stimulatory for endothelial cell migration [16] . These findings suggest that, when activated, VEGFR2 residence within early or late endosomes is prolonged and VEGF-A-stimulated signalling is perturbed with consequences for endothelial function depending on the exact location of VEGFR2 within the endosome-lysosome system.
However, the effects of VEGF-A on VEGFR2 degradation are contradictory. One study suggested that VEGFR2 undergoes almost complete degradation after VEGF-A stimulation for 120 min of stimulation with VEGF-A [11] , whereas another study suggested that VEGFR2 degradation was not significant [17] . Clearly, VEGFR2 can access late endosomes, as the use of chloroquine or bafilomycin A1 blocks VEGFR2 trafficking through endosomes and inhibits lysosomal degradation [11] . Chloroquine is a lysosomotropic drug that accumulates preferentially within acidic environments, such as endosomes and lysosomes, disrupting the internal pH and indirectly affecting trafficking. In contrast, bafilomycin A1 is a specific inhibitor of the vacuolar H + -ATPase and disrupts acidification, thus also affecting trafficking events. The use of leupeptin, pepstatin and E-64 [transepoxysuccinyl-L-leucylamido-(4-guanidino)butane] which block lysosomal protease activity also blocks VEGFR2 degradation and accumulation in a cathepsin D-positive compartment reminiscent of lysosomes [11] .
One model suggests that VEGFR2 is 'stored' primarily within two distinct compartments: in Rab4a-positive recycling endosomes linked to a short-loop recycling pathway to the plasma membrane, and in CD63-positive late endosomes [17] . In this model, VEGF-A stimulation increases levels of late endosomal VEGFR2, with only a low proportion exhibiting degradation in lysosomes. Interestingly, VEGFR2 was redistributed to the plasma membrane through a nonconventional novel recycling pathway which is dependent on c-Src tyrosine kinase activity [17] .
VEGFR2 ubiquitination and proteolysis
A characteristic feature of VEGFR2 activation is sequential tyrosine phosphorylation and ubiquitination followed by proteolysis (Figure 1 ). Analysis of VEGFR2 in primary human endothelial cells [11] , immortalized COS [18] and HEK (human embryonic kidney)-293 [19] cells clearly shows VEGFR2 ubiquitination and degradation. Although there is evidence for the proto-oncogene and RING (really interesting new gene) E3 ubiquitin ligase c-Cbl in mediating VEGFR2 ubiquitination [18, 20] , another study suggests a role for a different HECT (homologous with E6-associated protein C-terminus)-like E3 ubiquitin ligase, Nedd4 (neural-precursor-cell-expressed developmentally down-regulated 4) [19] . The use of a hybrid VEGFR2-IL2R (interleukin 2 receptor) fusion protein suggested that c-Cbl is recruited to VEGFR2 via the phosphorylated pTyr 1059 epitope and triggers PLCγ 1 ubiquitination and inhibition of angiogenesis in vitro [9] . Interestingly, genetic ablation of c-Cbl in Drosophila melanogaster leads to defects in oogenesis due to migration defects linked to loss of function of this Drosophila VEGFR orthologue [21] .
The adaptor protein Grb (growth-factor-receptor-bound protein) 10, which interacts through its SH2-and BPSdomains with VEGFR2, is elevated in response to VEGF-A and stimulates tyrosine phosphorylation of VEGFR2 which blocks Nedd4-mediated VEGFR2 degradation via a sequestering mechanism [19] . Hrs, a component of the ESCRT0 complex found on early endosomes can mediate ubiquitinated RTK sorting [22] [23] [24] . Hrs interacts with activated and phosphorylated VEGFR2 and can prevent Nedd4-regulated degradation of VEGFR2 probably due to the fact that it undergoes Nedd4-regulated ubiquitination [12] .
VEGFR1 localization to the Golgi apparatus is stimulus-dependent
The VEGFR1 gene is essential for vascular development [25] , but its function remains controversial. Mouse germline manipulation to express a truncated VEGFR1 molecule lacking the cytoplasmic domain produces no obvious defects [26] . VEGFR1 has 10-fold higher affinity for VEGF-A, but has 10-fold lower tyrosine kinase activity in comparison with VEGFR2 [27] . One hypothesis is that VEGFR1 acts as a VEGF-A trap to sequester cytokine, but forms a non-productive signalling complex [8] . Recently, it has been shown that substantial amounts of VEGFR1 are present within the biosynthetic secretory pathway, i.e. the Golgi apparatus, in both coronary and venous endothelial cells [28] . Approx. 80 % of total VEGFR1 was detected as a stable pool present within the Golgi apparatus; this localization was disrupted by use of Brefeldin A, a potent antibiotic that redistributes the Golgi to the ER (endoplasmic reticulum) [28] . Stimulation of primary endothelial cells with VEGF-A suggested transient redistribution to the plasma membrane via a TGN (trans-Golgi network)-to-plasma membrane route that is regulated by cytosolic calcium flux [28] . These studies suggest existence of a TGN-to-plasma membrane trafficking step in endothelial cells that is calcium-sensitive and distinct from constitutive endocytosis or regulated endocytosis involving dense core granules (e.g. WeibelPalade bodies). The initial binding and activation of VEGFR2 on the plasma membrane linked to the release of Ca 2+ ions from ER stores provides a negative-feedback model to regulate VEGF-A-based responses (Figure 2 ).
Detailed analysis of VEGFR-associated responses also suggests complexity in intracellular signalling pathways, cell migration and angiogenesis. Several potential VEGFR1-binding proteins have been identified using different systems, including the p85 subunit of phosphoinositide 3-kinase, PLCγ 1 and adaptor proteins such as SHP2 (SH2 domaincontaining protein tyrosine phosphatase 2), Grb2 and Nck [29] . However, these and other findings suggest that VEGFR1 may be linked to different spatially segregated intracellular signalling pathways that are linked to the plasma membrane, endosomes and Golgi apparatus (Figure 2 ). Different lines of evidence also argue that VEGFR1 activation regulates actin dynamics and cell migration [30, 31] . More recent data now also imply a positive regulatory role for VEGFR1 in pathological angiogenesis [29] . Deciphering how VEGFR1 function is linked to signalling in endothelial and nonendothelial tissues is essential in our understanding of how the VEGF-A response is regulated in the vascular system.
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